Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

BULERIA. Repositorio Institucional de la Universidad de León
Publication Tesis doctoral (DoctoralThesis)

Exploring p73 inhibition as a therapeutic target against glioblastoma stem cells, Explorando la inhibición de p73 como diana terapéutica frente a células troncales de glioblastoma

  • Villoch-Fernández, Javier
91 p., [ES] El Glioblastoma Multiforme (GBM) es el tumor más prevalente y letal de todos los que afectan al sistema nervioso central. El gen TP73 es un factor de transcripción que pertenece a la familia de p53. Este gen tiene 2 promotores, a partir de los cuales puede dar lugar a 2 isoformas, la isoforma TAp73, que contiene un dominio de transactivación, y la isoforma DNp73, que carece de este dominio. En este proyecto de tesis doctoral se plantea la hipótesis de que TAp73 es una diana terapéutica en glioblastoma. El objetivo general analiza el papel de TAp73 en Glioblastoma Stem Cells (GSC) e identifica y caracteriza posibles compuestos candidatos activos frente a GSC que modulen los niveles de TAp73., Ministerio de Economía y Competitividad, Junta de Castilla y León
BULERIA. Repositorio Institucional de la Universidad de León
Publication Artículo científico (JournalArticle)

A novel TAp73‐inhibitory compound counteracts stemness features of glioblastoma stem cells

  • Villoch Fernández, Javier
  • Martínez-García, Nicole
  • Martín López, Marta
  • Maeso Alonso, Laura
  • López Ferreras, Lorena
  • Vázquez Jiménez, Alberto
  • Muñoz Hidálgo, Lisandra
  • García Romero, Noemí
  • Sánchez López, José María
  • Fernandez, Antonio
  • Ayuso Sacido, Ángel
  • Marqués Martínez, Margarita
  • Marín Vieira, María Carmen
[En] Glioblastoma (GB) is the most common and fatal type of primary malignant brain tumor for which effective therapeutics are still lacking. GB stem cells, with tumor-initiating and self-renewal capacity, are mostly responsible for GB malignancy, representing a crucial target for therapies. The TP73 gene, which is highly expressed in GB, gives rise to the TAp73 isoform, a pleiotropic protein that regulates neural stem cell biology; however, its role in cancer has been highly controversial. We inactivated TP73 in human GB stem cells and revealed that TAp73 is required for their stemness potential, acting as a regulator of the transcriptional stemness signatures, highlighting TAp73 as a possible therapeutic target. As proof of concept, we identified a novel natural compound with TAp73-inhibitory capacity, which was highly effective against GB stem cells. The treatment reduced GB stem cell-invasion capacity and stem features, at least in part by TAp73 repression. Our data are consistent with a novel paradigm in which hijacking of p73-regulated neurodevelopmental programs, including neural stemness, might sustain tumor progression, pointing out TAp73 as a therapeutic strategy for GB., SI, This work was supported by Grants RTC-2015-3237-1 funded by MCIN/AEI/10.13039/501100011033, by ‘ERDF A way of making Europe’ (to MCM and Biomar Microbial Technologies), PID2019-105169RB-I00 funded by MCIN/AEI/10.13039/501100011033 (to MCM), and LE021P17 and LE022P20 from Junta de Castilla y Leon (cofinanced with FEDER funds). JV-F and LM-A were funded by Junta de Castilla y Leon. NM-G and AV-J are supported by predoctoral contracts from the Asociacion Espa nola contra el C ~ ancer (AECC) and Universidad de Leon, respectively. LM-H was a recipient of a postdoctoral contract from the Generalitat Valenciana.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Bioenergetics and redox adaptations of astrocytes to neuronal activity

  • Bolaños, Juan P.
Neuronal activity is a high-energy demanding process recruiting all neural cells that adapt their metabolism to sustain the energy and redox balance of neurons. During neurotransmission, synaptic cleft glutamate activates its receptors in neurons and in astrocytes, before being taken up by astrocytes through energy costly transporters. In astrocytes, the energy requirement for glutamate influx is likely to be met by glycolysis. To enable this, astrocytes are constitutively glycolytic, robustly expressing 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase-3 (PFKFB3), an enzyme that is negligibly present in neurons by continuous degradation because of the ubiquitin-proteasome pathway via anaphase-promoting complex/cyclosome (APC)-Cdh1. Additional factors contributing to the glycolytic frame of astrocytes may include 5′-AMP-activated protein kinase (AMPK), hypoxia-inducible factor-1 (HIF-1), pyruvate kinase muscle isoform-2 (PKM2), pyruvate dehydrogenase kinase-4 (PDK4), lactate dehydrogenase-B, or monocarboxylate transporter-4 (MCT4). Neurotransmission-associated messengers, such as nitric oxide or ammonium, stimulate lactate release from astrocytes. Astrocyte-derived glycolytic lactate thus sustains the energy needs of neurons, which in contrast to astrocytes mainly rely on oxidative phosphorylation. Neuronal activity unavoidably triggers reactive oxygen species, but the antioxidant defense of neurons is weak; hence, they use glucose for oxidation through the pentose-phosphate pathway to preserve the redox status. Furthermore, neural activity is coupled with erythroid-derived erythroid-derived 2-like 2 (Nrf2) mediated transcriptional activation of antioxidant genes in astrocytes, which boost the de novo glutathione biosynthesis in neighbor neurons. Thus, the bioenergetics and redox programs of astrocytes are adapted to sustain neuronal activity and survival. Developing therapeutic strategies to interfere with these pathways may be useful to combat neurological diseases., J.P.B. is funded by the MINECO (SAF2013‐41177‐R; RTC‐2015‐3237‐1), the Instituto de Salud Carlos III (RD12/0043/0021), the E.U. SP3‐People‐MC‐ITN programme (608381), the E.U. BATCure grant (666918), the European Regional Development Fund, and the NIH/NIDA (1R21DA037678‐01)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Mitochondrial control of cell bioenergetics in Parkinson's disease

  • Requejo-Aguilar, Raquel
  • Bolaños, Juan P.
PMCID: PMC5065935, Parkinson disease (PD) is a neurodegenerative disorder characterized by a selective loss of dopaminergic neurons in the substantia nigra. The earliest biochemical signs of the disease involve failure in mitochondrial-endoplasmic reticulum cross talk and lysosomal function, mitochondrial electron chain impairment, mitochondrial dynamics alterations, and calcium and iron homeostasis abnormalities. These changes are associated with increased mitochondrial reactive oxygen species (mROS) and energy deficiency. Recently, it has been reported that, as an attempt to compensate for the mitochondrial dysfunction, neurons invoke glycolysis as a low-efficient mode of energy production in models of PD. Here, we review how mitochondria orchestrate the maintenance of cellular energetic status in PD, with special focus on the switch from oxidative phosphorylation to glycolysis, as well as the implication of endoplasmic reticulum and lysosomes in the control of bioenergetics., J.P.B. is funded by the MINECO (SAF2013-41177-R; RTC-2015-3237-1), the ISCIII (RD12/0043/0021), the EU SP3-People-MC-ITN program (608381), the EU BATCure grant (666918), the NIH/NIDA (1R21DA037678-01)., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Current technical approaches to brain energy metabolism

  • Barros, L. Felipe
  • Bolaños, Juan P.
  • Bonvento, Gilles
  • Bouzier-Sore, Anne-Karine
  • Brown, Angus
  • Hirrlinger, Johannes
  • Kasparov, Sergey
  • Kirchhoff, Frank
  • Murphy, Anne N.
  • Pellerin, Luc
  • Robinson, Michael B.
  • Weber, Bruno
Neuroscience is a technology‐driven discipline and brain energy metabolism is no exception. Once satisfied with mapping metabolic pathways at organ level, we are now looking to learn what it is exactly that metabolic enzymes and transporters do and when, where do they reside, how are they regulated, and how do they relate to the specific functions of neurons, glial cells, and their subcellular domains and organelles, in different areas of the brain. Moreover, we aim to quantify the fluxes of metabolites within and between cells. Energy metabolism is not just a necessity for proper cell function and viability but plays specific roles in higher brain functions such as memory processing and behavior, whose mechanisms need to be understood at all hierarchical levels, from isolated proteins to whole subjects, in both health and disease. To this aim, the field takes advantage of diverse disciplines including anatomy, histology, physiology, biochemistry, bioenergetics, cellular biology, molecular biology, developmental biology, neurology, and mathematical modeling. This article presents a well‐referenced synopsis of the technical side of brain energy metabolism research. Detail and jargon are avoided whenever possible and emphasis is given to comparative strengths, limitations, and weaknesses, information that is often not available in regular articles., Fondecyt, Grant Number: 1160317; MINECO, Grant Numbers: SAF2016‐78114‐R and RTC‐2015‐3237‐1; CIBERFES, Grant Numer: CB16/10/00282; SP3‐People‐MC‐ITN program, Grant Number: 608381; EU BATCure, Grant Number: 666918; FEDER (European regional development fund); Investissement d'Avenir, Grant Number: ANR‐11‐INBS‐0011; French State in the context of the “Investments for the future” Program IdEx and the LabEx TRAIL, Grant Numbers: ANR‐10‐IDEX and ANR‐10‐LABX‐57; French–Swiss ANR‐FNS, Grant Numer: ANR‐15‐ CE37‐0012. University of Nottingham; BBSRC, Grant Numers: BB/L019396/1 and BB/K009192/1; MRC, Grant Number: MR/L020661/1; Deutsche Forschungsgemeinschaft, Grant Numers: DFG SPP 1757, SFB 894, and FOR 2289; European Commission, Grant Number: H2020‐FETPROACT 732344; Neurofibres, Grant Number: H2020‐MSCA‐ITN‐722053 EU‐GliaPhD; US National Institutes of Health, Grant Number: R01NS087611; Teva Pharmaceuticals; Agilent Technologies. IdEx, Grant Number: ANR‐10‐IDEX‐03‐02; French–Swiss ANR‐FNS, Grant number: 310030E‐164271; National Institutes of Neurologic Disease and Stroke at the National Institutes of Health, Grant Numer: R01 NS077773; University of Zurich and the Swiss National Science Foundation; Comisión Nacional de Investigación Científica y Tecnológica, Grant Numer: PB 01; Fondo Nacional de Desarrollo Científico y Tecnológico, Grant Numer: 1160317; Ministerio de Economía y Competitividad, Grant Numer: RTC‐2015‐3237‐1,SAF2016‐78114‐R; Agence Nationale de la Recherche, Grant Numers: ANR‐10‐IDEX, ANR‐10‐IDEX‐03‐02, ANR‐10‐LABX‐57, ANR‐11‐INBS‐0011, and ANR‐15‐ CE37‐0012; Biotechnology and Biological Sciences Research Council, Grant Numers: BB/L019396/1 and BB/K009192/1; Medical Research Council, Grant Numer: MR/L020661/1., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Mitochondrial respiratory chain disorganization in Parkinson's disease-relevant PINK1 and DJ1 mutants

  • López-Fabuel, Irene
  • Martín-Martín, Lucía
  • Resch-Beusher, Monica
  • Azkona, Garikoitz
  • Sánchez-Pernaute, Rosario
  • Bolaños, Juan P.
Brain mitochondrial complex I (CI) damage is associated with the loss of the dopaminergic neurons of the Substantia Nigra in Parkinson's Disease (PD) patients. However, whether CI inhibition is associated with any alteration of the mitochondrial respiratory chain (MRC) organization in PD patients is unknown. To address this issue, here we analyzed the MRC by blue native gel electrophoresis (BNGE) followed by western blotting, in mitochondria purified from fibroblasts of patients harboring PD-relevant Pink1 mutations. We found a decrease in free CI, and in free versus supercomplexes (SCs)-assembled CI in PD; however, free complex III (CIII) was only modestly affected, whereas its free versus SCs-assembled forms decreased. Interestingly, complex IV (CIV) was considerably lost in the PD samples. These results were largely confirmed in mitochondria isolated from cultured neurons from Pink1-/- mice, and in cultured neurons and forebrain samples from the PD-related Dj1-/- mice. Thus, besides CI damage, the MRC undergoes a profound structural remodeling in PD likely responsible for the energetic inefficiency and mitochondrial reactive oxygen species (mROS) over-production observed in this disease., J.P.B. is funded by MINECO (SAF2016-78114-R; RTC-2015-3237-1), CIBERFES (CB16/10/00282), E.U. SP3-People-MC-ITN programme (608381), EU BATCure grant (666918) and FEDER (European regional development fund). R.S.P. is funded by the Joint Program in Neurodegenerative Diseases (DAMNDPATHS)., Peer reviewed